Capstone Asset Management Co. decreased its stake in Natus Medical Incorporated (NASDAQ:BABY) by 7.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,259 shares of the medical equipment provider’s stock after selling 700 shares during the period. Capstone Asset Management Co.’s holdings in Natus Medical were worth $308,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in Natus Medical by 247.0% in the fourth quarter. Renaissance Technologies LLC now owns 45,800 shares of the medical equipment provider’s stock valued at $1,594,000 after buying an additional 32,600 shares during the last quarter. Norges Bank purchased a new stake in Natus Medical during the fourth quarter valued at approximately $11,560,000. Teachers Advisors LLC boosted its stake in Natus Medical by 4.7% in the fourth quarter. Teachers Advisors LLC now owns 307,029 shares of the medical equipment provider’s stock valued at $10,685,000 after buying an additional 13,783 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Natus Medical by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,400 shares of the medical equipment provider’s stock valued at $526,000 after buying an additional 200 shares during the last quarter. Finally, Legato Capital Management LLC boosted its stake in Natus Medical by 3,825.0% in the first quarter. Legato Capital Management LLC now owns 99,695 shares of the medical equipment provider’s stock valued at $2,540,000 after buying an additional 97,155 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Shares of Natus Medical Incorporated (BABY) traded up 1.36% during mid-day trading on Friday, hitting $33.55. 350,321 shares of the stock traded hands. Natus Medical Incorporated has a 52 week low of $32.83 and a 52 week high of $44.39. The stock has a 50-day moving average of $36.43 and a 200-day moving average of $36.70. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 58.15 and a beta of 0.93.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The company had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. During the same quarter in the prior year, the firm earned $0.39 EPS. The company’s revenue was up 27.3% compared to the same quarter last year. Analysts anticipate that Natus Medical Incorporated will post $1.70 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Capstone Asset Management Co. Lowers Stake in Natus Medical Incorporated (NASDAQ:BABY)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/13/capstone-asset-management-co-lowers-stake-in-natus-medical-incorporated-nasdaqbaby.html.

BABY has been the subject of several recent analyst reports. Benchmark Co. reaffirmed a “buy” rating and issued a $48.00 target price (down from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. TheStreet cut shares of Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $45.00.

In other news, Director Doris Engibous sold 5,000 shares of the stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $32.68, for a total transaction of $163,400.00. Following the transaction, the director now owns 22,650 shares in the company, valued at approximately $740,202. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider James B. Hawkins purchased 4,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were acquired at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the purchase, the insider now owns 578,023 shares in the company, valued at $19,641,221.54. The disclosure for this purchase can be found here. 5.50% of the stock is owned by corporate insiders.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.